Literature DB >> 3082496

Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women.

D González, G Ghiringhelli, C Mautalen.   

Abstract

Twenty-one women with primary osteoporosis received an intramuscular injection of 100 IU of salmon calcitonin at 8 AM. Blood samples IU of salmon calcitonin at 8 AM. Blood samples were collected up to 5 h postcalcitonin and urine was collected for 24 h in three periods of 8 h each. A significant fall of the total hydroxyproline excretion (THP) was observed in every period but the maximum effect took place 8-16 h postcalcitonin. The effect was more pronounced in those patients with a greater basal excretion of THP and in those with a more significant diminution of their bone mass. A significant diminution of the urinary excretion of calcium was found 8-24 h postcalcitonin, while phosphate excretion increased throughout the three 8 h periods. The effect of calcitonin in osteoporotic women was compared with the results obtained in 9 patients with Paget's disease. In absolute in 9 patients with Paget's disease. In absolute values the fall of THP excretion was significantly greater in the pagetic patients but the percentage diminution was not significantly different in osteoporotic women and in pagetic patients. Salmon calcitonin induced a significant acute diminution of bone turnover in patients with osteoporosis, as defined by decreases in total urinary hydroxyproline. The calcitonin-induced hypocalcemia does not seem to be an accurate index of the hormone action in osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082496     DOI: 10.1007/bf02556832

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  13 in total

1.  Modifications of a specific assay for hydroxyproline in urine.

Authors:  K I Kivirikko; O Laitinen; D J Prockop
Journal:  Anal Biochem       Date:  1967-05       Impact factor: 3.365

2.  Acute effects of calcitonin on bone formation in man.

Authors:  S M Krane; E D Harris; F R Singer; J T Potts
Journal:  Metabolism       Date:  1973-01       Impact factor: 8.694

3.  The acute response to calcitonin in Paget's disease: its relationship to the serum alkaline phosphatase level and the effect of phosphate treatment.

Authors:  H Gershberg; M Girgis; L Goldberg; J Duga; H St Paul
Journal:  J Clin Endocrinol Metab       Date:  1973-04       Impact factor: 5.958

4.  [Mineral bone content in a normal population of Buenos Aires].

Authors:  C Mautalen; C Tau; C Casco; G Fromm
Journal:  Medicina (B Aires)       Date:  1984       Impact factor: 0.653

5.  Long-term calcitonin therapy in postmenopausal osteoporosis.

Authors:  H E Gruber; J L Ivey; D J Baylink; M Matthews; W B Nelp; K Sisom; C H Chesnut
Journal:  Metabolism       Date:  1984-04       Impact factor: 8.694

6.  [Antiosteoclastic effect of calcitonin. Effect of a weak dose].

Authors:  M C Chapuy; P J Meunier
Journal:  Nouv Presse Med       Date:  1981-06-13

7.  Comparison of the acute effect of eel and salmon calcitonins in pagetic patients.

Authors:  M C Chapuy; P J Meunier
Journal:  Horm Metab Res       Date:  1982-10       Impact factor: 2.936

8.  The calcium lowering effect of synthetic human, porcine, and salmon calcitonin in patients with Paget's disease.

Authors:  L Galante; G F Joplin; I MacIntyre; N J Woodhouse
Journal:  Clin Sci       Date:  1973-06       Impact factor: 6.124

9.  [Induced hypocalcaemia test using salmon calcitonin as a means for the evaluation of osteoclastic activity (author's transl)].

Authors:  D Blanc; M C Chapuy; P Meunier
Journal:  Nouv Presse Med       Date:  1977 Aug 27-Sep 3

10.  Clinical evaluation of myeloma osteoclastic bone lesions: II. Induced hypocalcemia test using salmon calcitonin.

Authors:  R Bataille; J Sany
Journal:  Metab Bone Dis Relat Res       Date:  1982
View more
  7 in total

Review 1.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

2.  Failure of oral calcium to enhance the acute antiosteolytic effect of calcitonin.

Authors:  D C Gonzalez; C A Mautalen
Journal:  Calcif Tissue Int       Date:  1987-02       Impact factor: 4.333

3.  Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.

Authors:  D González; E Vega; G Ghiringhelli; C Mautalen
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

4.  Acute effects of nasal salmon calcitonin on calcium and bone metabolism.

Authors:  G Thamsborg; S G Skousgaard; H Daugaard; S Schifter; G Kollerup; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

5.  Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures.

Authors:  H Resch; P Pietschmann; R Willvonseder
Journal:  Calcif Tissue Int       Date:  1989-10       Impact factor: 4.333

Review 6.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

Review 7.  Understanding osteoporosis.

Authors:  R Marcus
Journal:  West J Med       Date:  1991-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.